Efficacy of docetaxel combined with oxaliplatin and fluorouracil against stage III/IV gastric cancer

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 48

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Dec 28, 2014; 20(48): 18413-18419
Published online Dec 28, 2014. doi: 10.3748/wjg.v20.i48.18413

Table 2 Main side effects of the 51 patients

Type	Side effects degree				Sum
Type	I	II	III	IV	Sum
Bone marrow suppression
leukopenia	6	9	10	13	38
Thrombocytopenia	5	3	4	1	13
anemia	6	5	2	1	14
Gastrointestinal reactions
Nausea, vomiting	23	14	8	3	48
SGOT/SGPT	5	4	2	0	11
Diarrhea	8	4	0	0	12
Oral mucositis	7	8	4	1	20
Baldness	17	5	3	0	25
Peripheral neuritis	12	1	0	0	13
Urea nitrogen	4	2	0	0	6
Creatinine	3	1	0	0	4

Citation: Yu YJ, Sun WJ, Lu MD, Wang FH, Qi DS, Zhang Y, Li PH, Huang H, You T, Zheng ZQ. Efficacy of docetaxel combined with oxaliplatin and fluorouracil against stage III/IV gastric cancer. World J Gastroenterol 2014; 20(48): 18413-18419
URL: https://www.wjgnet.com/1007-9327/full/v20/i48/18413.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i48.18413

Yu YJ, Sun WJ, Lu MD, Wang FH, Qi DS, Zhang Y, Li PH, Huang H, You T, Zheng ZQ. Efficacy of docetaxel combined with oxaliplatin and fluorouracil against stage III/IV gastric cancer. World J Gastroenterol 2014; 20(48): 18413-18419 [PMID: 25561810 DOI: 10.3748/wjg.v20.i48.18413]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.